In over four decades of history in glyco-oncology, TACAs themselves, and also TACAs on specific proteins and lipids, have been recognized as cancer antigens at high rankings (i.e., MUC1 in a second rank) based on comprehensive criteria such as therapeutic value, immunogenicity, specificity, and number of epitopes, etc. [21]. This evidence concerns the gene MUC1 and cancer.